Cilfa Opposition, Linaclotide, (Ar118601 A2)
No Annotations
Alert me when there are new annotations for this document
10 similar patent oppositions
-
CILFA opposition, semaglutide, (AR114353A1)
Countries: Argentina Date: 2021
-
CILFA opposition, osimertinib, (AR115019A2)
Countries: Argentina Date: 2021
-
CILFA opposition, cannabidiol, (AR115578A1)
Countries: Argentina Date: 2021
-
Fundación Grupo Efecto Positivo opposition, Doravirine (NNRTI), (ARP110101028)
Countries: Argentina Date: 2021
-
Fundación Grupo Efecto Positivo opposition, Remdesivir (GS-5734), (AR102468)
Countries: Argentina Date: 2021
-
CILFA opposition, celecoxib, (P990106069)
Countries: Argentina Date: 2004
-
CILFA opposition, carvedilol+hydrochlorothiazide, (P990105974)
Countries: Argentina Date: 2002
-
CILFA opposition, Nadifloxacin, (P990106490)
Countries: Argentina Date: 2002
-
CILFA opposition, fexofenadine+cyclodextrins, (P990105185)
Countries: Argentina Date: 2002
-
CILFA opposition, descarboetoxiloratadina, (P000103667 divisional of P990103342)
Countries: Argentina Date: 2002